全球老年黃斑部病變 (AMD) 治療市場研究報告 - 產業分析、規模、佔有率、成長、趨勢及預測（2025 年至 2033 年）

全球老年黃斑部病變 (AMD) 治療市場預計將大幅成長，到 2033 年將達到 277.2 億美元，高於 2024 年的 144.9 億美元。預計該市場在 2025 年至 2033 年期間的年複合成長率(CAGR) 為 7.48%。

老年黃斑部病變 (AMD) 治療市場正在快速發展，這得益於人口老化導致的 AMD 盛行率不斷上升，以及人們對視力和生活品質的日益重視。治療創新包括抗 VEGF 藥物、基因療法以及針對乾性和濕性 AMD 潛在病理生理機制的新型藥物傳遞系統。分子生物學和生物標記識別的進步使得個人化治療方法和早期介入成為可能。緩釋植入物和微創給藥技術正在提高患者的依從性和治療效果。

光學相干斷層掃描 (OCT) 等診斷影像技術與治療監測的結合，正在提高疾病管理的精確度。再生醫學和幹細胞療法的研究有望為視網膜功能恢復帶來希望。法規核准和報銷政策正在促進市場准入和應用。此外，認知度的提高和篩檢計畫的發展，正在推動早期診斷和治療的發展。

製藥公司、研究機構和醫療保健提供者之間的合作正在加速臨床試驗和產品開發。由於AMD仍然是全球視力喪失的主要原因，治療市場有望實現顯著成長，提供創新解決方案，滿足尚未滿足的醫療需求並改善患者的生活品質。

我們的報告經過精心設計，旨在為客戶提供關於各個行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵部分，以確保客戶全面了解市場格局：

市場概況：對市場的詳細介紹，包括定義、分類和行業現狀概述。

市場動態：深入分析影響市場成長的關鍵促進因素、限制因素、機會與挑戰。本部分探討技術進步、監管變化和新興趨勢等因素。

細分分析：根據產品類型、應用、最終用戶和地理位置等標準，將市場細分為不同的細分市場。此分析重點在於突出每個細分市場的表現和潛力。

競爭格局：對主要市場參與者的全面評估，包括其市場佔有率、產品組合、策略舉措和財務表現。本部分深入分析了領先公司的競爭動態和關鍵策略。

市場預測：根據歷史資料和當前市場狀況，對特定時期的市場規模和成長趨勢進行預測。這包括定量分析和圖形表示，以說明未來的市場發展軌跡。

區域分析：評估不同地理區域的市場表現，確定關鍵市場和區域趨勢。這有助於了解區域市場動態和機會。

新興趨勢與機會：識別當前及新興市場趨勢、技術創新和潛在投資領域。本部分提供對未來市場發展和成長前景的洞察。

涵蓋的細分市場列表

年齡相關性黃斑部病變 (AMD) 治療市場報告的此部分提供了國家和地區層面的細分詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按產品

• 艾莉亞
• 樂康
• 貝奧武
• 瓦比斯莫
• 西弗雷
• 阿瓦斯汀
• 其他產品

依疾病類型

• 濕性AMD
• 乾性 AMD

按年齡層

• 50-64歲
• 65-74歲
• 75歲以上

按配銷通路

• 醫院藥房
• 專業藥局和零售藥局
• 電子商務
• 報告中介紹的公司列表
• Amgen Inc., Apellis Pharmaceuticals Inc., Bayer AG, Biocon Biologics Ltd., Biogen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd, Formycon AG, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sandoz Group, Novartis AG, Pfizer Inc。

如果您有任何客製化需求，請聯絡我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

• 報告描述
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法
  • 市場研究流程
  • 市場研究方法

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：年齡相關性黃斑部病變 (AMD) 治療 - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業趨勢
• 波特五力分析
• 市場吸引力分析
  • 按產品進行市場吸引力分析
  • 依疾病類型分析市場吸引力
  • 按年齡分析市場吸引力
  • 按配銷通路分析市場吸引力
  • 市場吸引力分析：按地區

第4章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料製造商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第5章：全球老年性黃斑部病變（AMD）治療市場分析：依產品

• 按產品概覽
• 按產品進行的歷史和預測數據分析
• 艾莉亞
• 樂康
• 貝奧武
• 瓦比斯莫
• 西弗雷
• 阿瓦斯汀
• 其他產品

第6章：全球老年性黃斑部病變（AMD）治療市場分析：依疾病類型

• 依疾病類型概述
• 依疾病類型分析歷史和預測數據
• 濕性AMD
• 乾性 AMD

第7章：全球老年黃斑部病變（AMD）治療市場分析：依年齡層

• 按年齡層別概覽
• 按年齡層別進行的歷史和預測資料分析
• 50-64歲
• 65-74歲
• 75歲以上

第 8 章：全球老年性黃斑部病變 (AMD) 治療市場分析：按分銷管道

• 按配銷通路概覽
• 按配銷通路進行歷史和預測資料分析
• 醫院藥房
• 專業藥局和零售藥局
• 電子商務

第9章：全球老年性黃斑部病變（AMD）治療市場分析：按地區

• 區域展望
• 介紹
• 北美銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 北美各細分市場銷售分析
  • 北美各國銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 歐洲各細分市場銷售分析
  • 歐洲各國銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 亞太地區分部銷售分析
  • 亞太地區國家銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 拉丁美洲各細分市場銷售分析
  • 拉丁美洲各國銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 中東和非洲分部銷售分析
  • 中東和非洲國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東和非洲其他地區銷售分析

第 10 章：老年性黃斑部病變 (AMD) 治療公司的競爭格局

• 老年黃斑部病變（AMD）治療市場競爭
• 夥伴關係/合作/協議
• 併購
• 新產品發布
• 其他發展

第 11 章：公司簡介

• 頂級公司市佔率分析
• 市場集中度
• Amgen Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Apellis Pharmaceuticals Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Bayer AG
• 公司概況
• 公司收入
• 產品
• 最新動態
• Biocon Biologics Ltd.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Biogen Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Celltrion Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• F. Hoffmann-La Roche Ltd
• 公司概況
• 公司收入
• 產品
• 最新動態
• Formycon AG
• 公司概況
• 公司收入
• 產品
• 最新動態
• Novartis AG
• 公司概況
• 公司收入
• 產品
• 最新動態
• Pfizer Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Regeneron Pharmaceuticals Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Sandoz Group AG
• 公司概況
• 公司收入
• 產品
• 最新動態
• STADA Arzneimittel AG
• 公司概況
• 公司收入
• 產品
• 最新動態
• Xbrane Biopharma AB
• 公司概況
• 公司收入
• 產品
• 最新動態

注意 - 在公司簡介中，財務細節和最新發展取決於可用性，或者在私人公司的情況下可能不涵蓋

Global Age Related Macular Degeneration (AMD) Therapeutics Market is poised to witness substantial growth, reaching a value of USD 27.72 Billion by the year 2033, up from USD 14.49 Billion attained in 2024. The market is anticipated to display a Compound Annual Growth Rate (CAGR) of 7.48% between 2025 and 2033.

The age-related macular degeneration (AMD) therapeutics market is advancing rapidly, driven by the increasing prevalence of AMD due to aging populations and the growing focus on preserving vision and quality of life. Therapeutic innovations encompass anti-VEGF agents, gene therapies, and novel drug delivery systems targeting the underlying pathophysiology of both dry and wet AMD forms. Advances in molecular biology and biomarker identification are enabling personalized treatment approaches and earlier intervention. Sustained-release implants and minimally invasive administration techniques are improving patient compliance and treatment outcomes.

The integration of diagnostic imaging technologies, such as optical coherence tomography (OCT), with therapeutic monitoring is enhancing disease management precision. Research into regenerative medicine and stem cell therapies holds promise for restoring retinal function. Regulatory approvals and reimbursement policies are facilitating market access and adoption. Additionally, increasing awareness and screening programs are driving early diagnosis and treatment initiation.

Collaborations among pharmaceutical companies, research institutions, and healthcare providers are accelerating clinical trials and product development. As AMD remains a leading cause of vision loss globally, the therapeutics market is poised for significant growth, delivering innovative solutions that address unmet medical needs and improve patient quality of life.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Age Related Macular Degeneration (AMD) Therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Eylea
• Lucentis
• Beovu
• Vabysmo
• Syfovre
• Avastin
• Other Products

By Disease Type

• Wet AMD
• Dry AMD

By Age Group

• 50-64 Years
• 65-74 Years
• 75 and Above

By Distribution Channel

• Hospital Pharmacies
• Specialty and Retail Pharmacies
• E-Commerce
• List of Companies Profiled in the report
• Amgen Inc., Apellis Pharmaceuticals Inc., Bayer AG, Biocon Biologics Ltd., Biogen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd, Formycon AG, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sandoz Group AG, STADA Arzneimittel AG, Xbrane Biopharma AB

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Disease Type
  • 3.7.3 Market Attractiveness Analysis By Age Group
  • 3.7.4 Market Attractiveness Analysis By Distribution Channel
  • 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY PRODUCT

• 5.1. Overview By Product
• 5.2. Historical and Forecast Data Analysis By Product
• 5.3. Eylea Historic and Forecast Sales By Regions
• 5.4. Lucentis Historic and Forecast Sales By Regions
• 5.5. Beovu Historic and Forecast Sales By Regions
• 5.6. Vabysmo Historic and Forecast Sales By Regions
• 5.7. Syfovre Historic and Forecast Sales By Regions
• 5.8. Avastin Historic and Forecast Sales By Regions
• 5.9. Other Products Historic and Forecast Sales By Regions

6. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY DISEASE TYPE

• 6.1. Overview By Disease Type
• 6.2. Historical and Forecast Data Analysis By Disease Type
• 6.3. Wet AMD Historic and Forecast Sales By Regions
• 6.4. Dry AMD Historic and Forecast Sales By Regions

7. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY AGE GROUP

• 7.1. Overview By Age Group
• 7.2. Historical and Forecast Data Analysis By Age Group
• 7.3. 50-64 Years Historic and Forecast Sales By Regions
• 7.4. 65-74 Years Historic and Forecast Sales By Regions
• 7.5. 75 and Above Historic and Forecast Sales By Regions

8. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 8.1. Overview By Distribution Channel
• 8.2. Historical and Forecast Data Analysis By Distribution Channel
• 8.3. Hospital Pharmacies Historic and Forecast Sales By Regions
• 8.4. Specialty and Retail Pharmacies Historic and Forecast Sales By Regions
• 8.5. E-Commerce Historic and Forecast Sales By Regions

9. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS COMPANIES

• 10.1. Age Related Macular Degeneration (AMD) Therapeutics Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Amgen Inc.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Apellis Pharmaceuticals Inc.
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Bayer AG
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Biocon Biologics Ltd.
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Biogen Inc.
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Celltrion Inc.
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. F. Hoffmann-La Roche Ltd
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Formycon AG
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Novartis AG
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Pfizer Inc.
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Regeneron Pharmaceuticals Inc.
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. Sandoz Group AG
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments
• 11.15. STADA Arzneimittel AG
  • 11.15.1 Company Overview
  • 11.15.2 Company Revenue
  • 11.15.3 Products
  • 11.15.4 Recent Developments
• 11.16. Xbrane Biopharma AB
  • 11.16.1 Company Overview
  • 11.16.2 Company Revenue
  • 11.16.3 Products
  • 11.16.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Product (USD MN)
• Eylea Market Sales By Geography (USD MN)
• Lucentis Market Sales By Geography (USD MN)
• Beovu Market Sales By Geography (USD MN)
• Vabysmo Market Sales By Geography (USD MN)
• Syfovre Market Sales By Geography (USD MN)
• Avastin Market Sales By Geography (USD MN)
• Other Products Market Sales By Geography (USD MN)
• Analysis By Disease Type (USD MN)
• Wet AMD Market Sales By Geography (USD MN)
• Dry AMD Market Sales By Geography (USD MN)
• Analysis By Age Group (USD MN)
• 50-64 Years Market Sales By Geography (USD MN)
• 65-74 Years Market Sales By Geography (USD MN)
• 75 and Above Market Sales By Geography (USD MN)
• Analysis By Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales By Geography (USD MN)
• Specialty and Retail Pharmacies Market Sales By Geography (USD MN)
• E-Commerce Market Sales By Geography (USD MN)
• Global Age Related Macular Degeneration (AMD) Therapeutics Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Age Related Macular Degeneration (AMD) Therapeutics Report
• Market Research Process
• Market Research Methodology
• Global Age Related Macular Degeneration (AMD) Therapeutics Market Size, By Regions (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Product
• Market Attractiveness Analysis By Disease Type
• Market Attractiveness Analysis By Age Group
• Market Attractiveness Analysis By Distribution Channel
• Market Attractiveness Analysis By Regions
• Value Chain Analysis
• Global Market Analysis By Product (USD MN)
• Eylea Market Sales By Geography (USD MN)
• Lucentis Market Sales By Geography (USD MN)
• Beovu Market Sales By Geography (USD MN)
• Vabysmo Market Sales By Geography (USD MN)
• Syfovre Market Sales By Geography (USD MN)
• Avastin Market Sales By Geography (USD MN)
• Other Products Market Sales By Geography (USD MN)
• Global Market Analysis By Disease Type (USD MN)
• Wet AMD Market Sales By Geography (USD MN)
• Dry AMD Market Sales By Geography (USD MN)
• Global Market Analysis By Age Group (USD MN)
• 50-64 Years Market Sales By Geography (USD MN)
• 65-74 Years Market Sales By Geography (USD MN)
• 75 and Above Market Sales By Geography (USD MN)
• Global Market Analysis By Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales By Geography (USD MN)
• Specialty and Retail Pharmacies Market Sales By Geography (USD MN)
• E-Commerce Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.